Latest Announcements
Ladenburg Acts as Sole Book-Running Manager in the $3.6 Million Underwritten Public Offering for Catheter Precision Inc.
Transaction Information Catheter Precision, Inc. (NYSEAM:VTAK) announced the closing of its public offering of 805,900 common stock units, including 458,623 common stock units issued upon exercise of the...
Ladenburg Acts as Co-Manager in the $100 Million Public Offering for Oxford Lane Capital Corp.
Transaction Information Oxford Lane Capital Corp. (NASDAQ:OXLC) priced an underwritten public offering of $100,000,000 in aggregate principal amount of 8.75% unsecured notes maturing on June 30, 2030. The notes may...
Ladenburg Acts as Sole Placement Agent in the $5 Million Registered Direct Offering for Biodexa Pharmaceuticals
Transaction Information Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the closing of its registered direct offering of $5 Million consisting of American Depository Shares, Pre-Funded Warrants and Warrants to...
Ladenburg Acts as Sole Bookrunning Manager in the $3.87 Million Underwritten Public Offering for NovaBay Pharmaceuticals, Inc.
Transaction Information NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants,...
Ladenburg Acts as Co-Manager in the $107.5 Million Offering for UroGen Pharma Ltd
Transaction InformationUroGen Pharma Ltd. (Nasdaq: URGN) announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain...
Ladenburg Acts as Exclusive Placement Agent in the $3.4 Million Offering for Sonnet BioTherapeutics Holdings, Inc.
Transaction Information Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet") announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to...
Ladenburg Thalmann & Co. Inc. Elevates Executive Leadership with Co-CEO Appointments
NEW YORK, May 15, 2024 /PRNewswire/ -- Ladenburg Thalmann & Co. Inc., a prominent middle market investment bank, is pleased to announce the appointment of Barry Steiner and Mike Gideon as co-Chief Executive...
Ladenburg Thalmann acts as Lead Bookrunner for Great Elm Capital Corp. on its Notes Offering of $30.0 Million
Ladenburg Thalmann served as Lead Bookrunner for this offering. Since 2017, Ladenburg has led 60 fixed income transactions for BDC/Investment Companies raising over $2.7 Billion. Overall, Ladenburg has...
Ladenburg Thalmann Acts as Sole Placement Agent for Calidi Biotherapeutics, Inc. in their $6.1 Million Public Offering
Transaction Information Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi") announced the closing of its public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and...
Ladenburg Acts as Exclusive Placement Agent in $6.5 Million Financing for Biodexa Pharmaceuticals
Ladenburg also acts as Exclusive Advisor for In-License of Phase 3 Ready Asset, eRapa for Familial Adenomatous Polyposis (FAP) Transaction Information Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced $6.5...
Ladenburg Acts as Exclusive Placement Agent for Intelligent Bio Solutions in their $10.1 Million Private Placement
Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company") announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of...
Ladenburg Acts as Exclusive Placement Agent in the $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules for Palisade Bio, Inc.
Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) announced that it has closed its private placement with an institutional investor for the purchase of shares of common stock (or certain pre-funded warrants...